Oramed Pharmaceuticals Inc. (ORMP) Stock

Oramed Pharmaceuticals Inc. (ORMP) is a Healthcare stock trading at $4.80 (as of 2026-08-21), with a market capitalization of $199.67M and a trailing P/E of 3.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oramed Pharmaceuticals Inc. develops pharmaceutical products including orally delivered capsule and pill formulations intended for diabetes treatment and for delivering polypeptides. Its pipeline includes ORMD-0801 (an oral insulin capsule) and ORMD-0901 (an oral capsule for type 2 diabetes), along with development of an oral leptin capsule for weight loss.

Understand Oramed Pharmaceuticals Inc.: how it makes money

Oramed Pharmaceuticals develops orally ingestible drug candidates, including an oral insulin capsule (ORMD-0801), and other oral capsule therapies for diabetes and related conditions, with its work centered on clinical trials such as ORMD-0801 Phase 3 and ORMD-0901 Phase 1.

Its progress toward economic scale is structurally tied to executing its oral insulin Phase 3 program (ORA-D-013-1) while also advancing other capsule candidates like ORMD-0901 through their trial stages.

Business quality (Mixed): Clear pipeline focus (oral capsule programs) with observable clinical-trial operating metrics, but limited company-level operating context in the provided data (no reportable segments, and revenue is shown as 0.0 for the latest period).

Valuation: At 2× earnings, ORMP trades 89% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Clinical advancement signal for ORMD-0801 oral insulin: ORMD-0801 has completed Phase II trials, and it is now in Phase 3 activity with ORA-D-013-1 Participants Enrolled reported at 710.0.
  • Multiple oral capsule programs in development: It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed Phase I trials, and it has additional efforts such as an oral leptin treatment and Oravax vaccine cohort activity.

Bear case

  • Development and execution risk: Phase 3 execution may be challenging, as the provided metrics show ORA-D-013-1 Participants Enrolled at 710.0 while ORA-D-013-2 Planned Patient Count is 60.0.
  • Current profitability profile is weak in the latest period shown: For the period 2025-09-30, operating_margin_pct is -121.3, indicating substantial operating losses.
Valuation — source: SEC EDGAR (first-party)
Price$4.80
Market Cap$199.67M
P/E Ratio3.9
Price / Book0.63
Price / Sales37.39
FCF Yield-4.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.00M
Net Margin3202.5%
Financial Health — source: SEC EDGAR
Altman Z-Score3.38 (safe)
Valuation vs Sector & Industry
Stock P/E3.9
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
vs Sector-81.9%
vs Industry-76.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBML Capital Management, LLC ($10.77M)
Institutional Holders Tracked10
Congressional Trades (recent)4
Company
SectorHealthcare
IndustryPharmaceutical Products
CEONadav Kidron
Employees13
CountryUS
IPO Date2007-05-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • AN2 Therapeutics, Inc. (ANTX)
  • SIGA Technologies, Inc. (SIGA)
  • PepGen Inc. (PEPG)
  • Journey Medical Corporation (DERM)
  • Corbus Pharmaceuticals Holdings, Inc. (CRBP)
  • Tonix Pharmaceuticals Holding Corp. (TNXP)
  • Korro Bio, Inc. (KRRO)
  • Nkarta, Inc. (NKTX)
ORMP earnings history · ORMP institutional & insider holders · ORMP KPIs & operating metrics · ORMP financials · ORMP investor presentations & press releases · ORMP SEC filings · ORMP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.